Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses non-medical switching of patients from high-cost reference biologics to biosimilars (or to other therapies).
Transcript:
What is your position on non-medical switching from biologics to biosimilars?
Non-medical switching is when insurance companies reduce formulary coverage, which puts financial pressure on patients to switch their prescription medications to alternative therapies. In many cases, the alternative therapies that the patients are being pressured to switch to are made by manufacturers that have successfully produced lower bids than the existing preferred drug from a different manufacturer on the plan.
Reductions in coverage include increased out-of-pocket costs, eliminating a drug from the formulary entirely, or creating restrictions around access.
The Global Healthy Living Foundation is opposed to non-medical switching, particularly when a payer changes their formulary in the middle of a contract year because they are not honoring the contract their customers signed. Patients are not getting what they paid premiums for, or met deductible requirements to access.
This puts chronic disease patients at risk because it can often take months or years to find an effective treatment. Should access to that treatment be reduced or shifted suddenly, delays in treatment or needing to switch treatments could have very harmful health consequences.
Every year, there is something called the “open enrollment period.” (The 2018 enrollment period was between November 1 and December 15, 2017, for those purchasing health insurance through the federal marketplace.) Most people who purchase commercial health insurance will have at least a few weeks to read through proposed contracts, evaluate the doctors in the health plan network and review the available formulary to select a health insurance plan and provider from the options available to them.
Then, once the health insurance contract is signed, a patient and their covered family members, if applicable, are locked in for at least a year. But what may not be apparent is that in many states (such as Florida, Tennessee, and Massachusetts), in those states, the insurer is allowed to alter the contract by reducing their drug coverage at any time during the plan year. Therefore, not only is the contract unfair to consumers, but it puts patients’ health at risk when access to their medication becomes uncertain.
Health insurance companies claim that adjusting the formulary is a way to keep healthcare costs down. However, reducing drug costs to benefit their own profitability is quite shortsighted. Patients who get sicker (because of falling out of remission) if their treatment is altered are likely to see the doctor more, need more diagnostic tests and, generally, increase their healthcare utilization.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.